Orexigen Announces Second Quarter 2017 Financial Results

Published: Aug 09, 2017

SAN DIEGO, Aug. 8, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2017.

"Our performance in the second quarter of 2017 reflects the successful implementation of our commercial strategy that we launched late last year. The team at Orexigen has delivered dramatic growth of U.S. Contrave sales in the first half of 2017," said Mike Narachi, President and Chief Executive Officer of Orexigen.

Back to news